Argenica Therapeutics Trials New Treatment to Protect the Brain after a Stroke

The MTPConnect Podcast

Perth- based biotech Argenica Therapeutics is developing therapies to treat stroke and other neurological conditions. A new neuroprotective peptide treatment is now being tested for ischaemic stroke patients presenting to emergency departments at 10 hospitals around Australia and is expected to improve patient outcomes by protecting the brain tissue from dying until blood flow can be restored.
CEO and Managing Director Dr Liz Dallimore joins hosts Caroline Duell and WA Life Sciences Innovation Hub Director, Dr Tracey Wilkinson, to discuss the company’s journey from research institute spinout, working with the US FDA, the benefits of conducting clinical trials in Australia, the challenges of raising capital, and why she is passionate about representing the biotech sector on various boards.